Insider Buying: InspireMD (NYSE:NSPR) Director Acquires 15,995 Shares of Stock

Key Points

• InspireMD director Scott Ward bought 15,995 shares on May 6 at an average price of $1.15 per share, a transaction worth about $18,394.25. After the purchase, Ward’s holdings rose to 163,841 shares, a 10.82% increase in his position.
• The stock was trading near $1.15, down 0.9% in Friday mid-day trading, with volume above its recent average. InspireMD remains well below its 52-week high of $2.93 and has a market cap of about $53.93 million.
• Analysts remain mostly bullish on InspireMD despite recent price-target reductions. The stock currently has a consensus rating of “Buy” and an average target price of $4.50.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Scott Ward acquired 15,995 shares of the business's stock in a transaction on Wednesday, May 6th. The shares were bought at an average cost of $1.15 per share, with a total value of $18,394.25. Following the completion of the acquisition, the director owned 163,841 shares of the company's stock, valued at approximately $188,417.15. This trade represents a 10.82% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

InspireMD Trading Down 0.9%

Shares of InspireMD stock traded down $0.01 during mid-day trading on Friday, reaching $1.15. 261,553 shares of the stock were exchanged, compared to its average volume of 174,764. InspireMD, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.93. The company has a market cap of $53.93 million, a price-to-earnings ratio of -1.53 and a beta of 0.82. The firm has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $1.75.

Institutional Trading of InspireMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. increased its stake in shares of InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company's stock valued at $101,000 after buying an additional 10,000 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company's stock valued at $91,000 after buying an additional 11,778 shares in the last quarter. Rosalind Advisors Inc. increased its stake in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company's stock valued at $5,196,000 after buying an additional 14,109 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of InspireMD in the fourth quarter valued at $30,000. Finally, Virtu Financial LLC acquired a new stake in shares of InspireMD in the fourth quarter valued at $31,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Piper Sandler reissued an "overweight" rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday. Lake Street Capital set a $4.00 price objective on InspireMD in a research report on Monday. Loop Capital set a $5.00 price objective on InspireMD in a research note on Tuesday, February 24th. Finally, Maxim Group initiated coverage on InspireMD in a research note on Monday, February 2nd. They issued a "buy" rating and a $6.00 target price for the company. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.